Skip to main content
SpringerLink
Log in
Book cover

Ischemic Stroke Therapeutics pp 99–104Cite as

Heterogeneous Causes of Stroke: Antithrombotics

  • Chapter

  • 2144 Accesses

Abstract

In the United States, stroke is the fourth leading cause of death and a major reason for disability. Those who survive the initial event are at a high risk of recurrence. Recurrent ischemic events account for up to a quarter of annual strokes. Hence, selecting the appropriate antithrombotic to reduce the risk of recurrent stroke is of utmost importance. Appropriate and judicious use of medications for secondary prevention of stroke or TIA can lead to considerable reduction of healthcare costs and decrease the burden of stroke in general. In patients without atrial fibrillation, secondary prevention with antiplatelet drugs has been proven effective along with other risk factor modifiers to reduce recurrence. Currently, antiplatelet agents (e.g., Aspirin, Clopidogrel, Aspirin plus Dipyridamole) are being used for the secondary prevention of stroke.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American heart association/American stroke association. Stroke. 2011;42(1):227–76.

    Article  PubMed  Google Scholar 

  2. Katz BS, Flemming KD. Antithrombotic selection and risk factor management in ischemic stroke and transient ischemic attack. Neurosurg Focus. 2014;36(1):E10.

    Article  PubMed  Google Scholar 

  3. Hankey GJ, Warlow CP. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet. 1999;354(9188):1457–63.

    Article  CAS  PubMed  Google Scholar 

  4. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American heart association/American stroke association. Stroke. 2014;45:2160–236.

    Article  PubMed  Google Scholar 

  5. Johnson ES, Lanes SF, Wentworth CE, Satterfield MH, Abebe BL, Dicker LW. A metaregression analysis of the dose–response effect of aspirin on stroke. Arch Intern Med. 1999;159:1248–53.

    Article  CAS  PubMed  Google Scholar 

  6. Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353(22):2373–83.

    Article  CAS  PubMed  Google Scholar 

  7. Antithrombotics trialists' collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86.

    Article  Google Scholar 

  8. The Dutch TIA trial study group. A comparison of two doses of Aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med. 1991;325:1261–6.

    Article  Google Scholar 

  9. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991;54(12):1044–54.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol. 2005;95(10):1218–22.

    Article  CAS  PubMed  Google Scholar 

  11. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet. 1997;349:1569–81.

    Article  Google Scholar 

  12. CAST (Chinese Acute Stroke Trial) collaborative group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet. 1997;349:1641–9.

    Article  Google Scholar 

  13. Sandercock PAG, Counsell C, Gubitz GJ, Tseng MC. Antiplatelet therapy for acute ischaemic stroke. Cochrane Database of Syst Rev. 2008;3.

    Google Scholar 

  14. Jauch EC, Saver JL, Adams HP, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870–947.

    Article  PubMed  Google Scholar 

  15. Lansberg MG, O’Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e601S–36.

    CAS  PubMed Central  PubMed  Google Scholar 

  16. The Canadian cooperative study group. A randomized trial of Aspirin and Sulfinpyrazone in threatened stroke. N Engl J Med. 1978;299:53–9.

    Article  Google Scholar 

  17. Mohr JP, Tompson JLP, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345:1444–51.

    Article  CAS  PubMed  Google Scholar 

  18. Gorelick PB, Kelly M, Ruland S, Harris Y, Kittner S. Aspirin and ticlopidine for prevention of recurrent stroke in black patients. JAMA. 2014;289(22):2947–57.

    Article  Google Scholar 

  19. Hankey GJ. Secondary stroke prevention. Lancet Neurol. 2013;13(2):178–94.

    Article  PubMed  Google Scholar 

  20. Savcic M, Hauert J, Bachmann F, Wyld PJ, Geudelin B, Cariou R. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost. 1999;25 Suppl 2:15–9.

    CAS  PubMed  Google Scholar 

  21. Diener H-C, Sacco RL, Yusuf S, et al. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFE). Lancet Neurol. 2008;7(10):875–84.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Diener H-C, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9431):331–7.

    Article  CAS  PubMed  Google Scholar 

  23. Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369(1):11–9.

    Article  CAS  PubMed  Google Scholar 

  24. Johnston SC, Easton JD, Farrant M, et al. Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design. Int J Stroke. 2013;8(6):479–83.

    Article  PubMed Central  PubMed  Google Scholar 

  25. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–39.

    Article  Google Scholar 

  26. Sudlow CLM, Mason G, Maurice JB, Wedderburn CJ, Hankey GJ. Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst Rev. 2009;(4): CD001246

    Google Scholar 

  27. Wong KSL, Wang Y, Leng X, et al. Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis. Circulation. 2013;128(15):1656–66.

    Article  CAS  PubMed  Google Scholar 

  28. Lau AY, Zhao Y, Chen C, et al. Dual antiplatelets reduce microembolic signals in patients with transient ischemic attack and minor stroke: subgroup analysis of CLAIR study. Int J Stroke. 2013;1–6.

    Google Scholar 

  29. Lee M, Saver JL, Hong KS, Rao NM, Wu YL, Ovbiagele B. Risk–benefit profile of long-term dual-versus single-antiplatelet therapy among patients with ischemic stroke. Ann Intern Med. 2013;159:463–70.

    Article  PubMed  Google Scholar 

  30. Triple Antiplatelets for Reducing Dependency After Ischaemic Stroke (TARDIS). https://clinicaltrials.gov/ct2/show/NCT01661322

  31. The ESPS group. The European stroke prevention study. Lancet. 1987;2(8572):1351–4.

    Google Scholar 

  32. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143(1–2):1–13.

    Article  CAS  PubMed  Google Scholar 

  33. Leonardi-Bee J, Bath PMW, Bousser M-G, et al. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke. 2005;36(1):162–8.

    Article  CAS  PubMed  Google Scholar 

  34. Verro P, Gorelick PB, Nguyen D. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. Stroke. 2008;39(4):1358–63.

    Article  CAS  PubMed  Google Scholar 

  35. Commentary SM. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Perspect Vasc Surg Endovasc Ther. 2007;19(1):87–9.

    Article  Google Scholar 

  36. Halkes PH, Gray LJ, Bath PMW, et al. Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk. J Neurol Neurosurg Psychiatry. 2008;79(11):1218–23.

    Article  CAS  PubMed  Google Scholar 

  37. Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol. 2010;9(10):959–68.

    Article  CAS  PubMed  Google Scholar 

  38. Huang Y, Cheng Y, Wu J, et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol. 2008;7(6):494–9.

    Article  CAS  PubMed  Google Scholar 

  39. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989;1(8649):1215–20.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclaimer

The opinions expressed herein belong solely to the authors. They are neither those of nor endorsed by the Uniformed Services University of the Health Sciences, Department of Defense, or any other agency of the federal government.

Author information

Authors and Affiliations

  1. Division of Neurocritical Care, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

    Atul Ashok Kalanuria M.D.

  2. Department of Neurology, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD, 20814, USA

    Geoffrey Ling M.D., Ph.D.

Authors
  1. Atul Ashok Kalanuria M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Geoffrey Ling M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Geoffrey Ling M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Admiral Pihl Professor and Chairman of Neurology, Medical University of South Carolina, Charleston, South Carolina, USA

    Bruce Ovbiagele

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Kalanuria, A.A., Ling, G. (2016). Heterogeneous Causes of Stroke: Antithrombotics. In: Ovbiagele, B. (eds) Ischemic Stroke Therapeutics. Springer, Cham. https://doi.org/10.1007/978-3-319-17750-2_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-17750-2_10

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-17749-6

  • Online ISBN: 978-3-319-17750-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation